These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

157 related items for PubMed ID: 33854670

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. [From Hemoglobin SS to SF: interest of hydroxyurea in the management of sickle cell disease in two Congolese children and review of the literature].
    Nkashama GM, Wakamb GK, Mulangu AM, Nkashama GM, Kupa BK, Numbi OL.
    Pan Afr Med J; 2015; 21():124. PubMed ID: 26327961
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Making hydroxyurea affordable for sickle cell disease in Tanzania is essential (HASTE): How to meet major health needs at a reasonable cost.
    Costa E, Tibalinda P, Sterzi E, Leufkens HMG, Makani J, Kaale E, Luzzatto L.
    Am J Hematol; 2021 Jan; 96(1):E2-E5. PubMed ID: 32974896
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Management of sickle cell disease: current practices and challenges in a northeastern region of the Democratic Republic of the Congo.
    Kambale-Kombi P, Marini Djang'eing'a R, Alworong'a Opara JP, Minon JM, Boemer F, Bours V, Tonen-Wolyec S, Kayembe Tshilumba C, Batina-Agasa S.
    Hematology; 2021 Dec; 26(1):199-205. PubMed ID: 33594960
    [Abstract] [Full Text] [Related]

  • 12. Barriers to the use of hydroxyurea in the management of sickle cell disease in Nigeria.
    Adeyemo TA, Diaku-Akinwunmi IN, Ojewunmi OO, Bolarinwa AB, Adekile AD.
    Hemoglobin; 2019 May; 43(3):188-192. PubMed ID: 31462098
    [Abstract] [Full Text] [Related]

  • 13. Newborn screening for sickle cell disease in Butembo and Beni: a pilot experience in a highland region of the Democratic Republic of Congo.
    Mumbere M, Batina-Agasa S, Uvoya NA, Kasai ET, Kombi PK, Djang'eing'a RM, Opara JA.
    Pan Afr Med J; 2023 May; 45():56. PubMed ID: 37637401
    [Abstract] [Full Text] [Related]

  • 14. Low-dose hydroxycarbamide therapy may offer similar benefit as maximum tolerated dose for children and young adults with sickle cell disease in low-middle-income settings.
    Inusa BPD, Wale A, Hassan AA, Idhate T, Dogara L, Ijei I, Qin Y, Anie K, Lawson JO, Hsu L.
    F1000Res; 2018 May; 7():. PubMed ID: 30228870
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Barriers to hydroxyurea adherence and health-related quality of life in adolescents and young adults with sickle cell disease.
    Badawy SM, Thompson AA, Penedo FJ, Lai JS, Rychlik K, Liem RI.
    Eur J Haematol; 2017 Jun; 98(6):608-614. PubMed ID: 28306171
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Hydroxyurea in the treatment of sickle-cell anemia.
    Howard LW, Kennedy LD.
    Ann Pharmacother; 1997 Nov; 31(11):1393-6. PubMed ID: 9391697
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.